All In Biotech

Drug Trial Radar · NCT00490139

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,381

Actual

Start

May 16, 2007

Primary completion

Dec 6, 2013

Study completion Jul 1, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; Canadian Cancer Trials Group
First posted
Jun 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.

Conditions

  • Neoplasms, Breast

Interventions

  • LapatinibDrug

    Small molecule inhibitor

  • TrastuzumabBiological

    Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) at the Primary AnalysisTime frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)

Locations

924 sites in 44 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Anchorage, Alaska

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Duarte, California

  • Novartis Investigative Site

    Fairfield, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Martinez, California

  • Novartis Investigative Site

    Marysville, California

  • Novartis Investigative Site

    Mountain View, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Pleasanton, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Thornton, Colorado

  • Novartis Investigative Site

    Wheat Ridge, Colorado

  • Novartis Investigative Site

    Hartford, Connecticut

  • Novartis Investigative Site

    New Haven, Connecticut

  • Novartis Investigative Site

    Dover, Delaware

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Lakeland, Florida

  • Novartis Investigative Site

    Ocala, Florida

  • Novartis Investigative Site

    Orlando, Florida

Showing 40 of 924 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.